What types of adverse reactions were reported when taking Olysio®?
UPDATE: Janssen Therapeutics discontinued Olysio effective May 25, 2018.
In clinical studies, the most common adverse reactions occurring in more than 20% of participants include:
- rash, including photosensitivity, pruritus (severe itching) and nausea during the first 12 weeks of treatment in participants receiving Olysio® with peginterferon alfa and ribavirin.
- those receiving Olysio® with sofosbuvir during the 12 or 24 weeks of treatment experienced fatigue, headache and nausea.
Last Updated: May 2018
A New Chronic Hepatitis C Treatment - Olysio (simeprevir). http://www.olysio.com/, Janssen Therapeutics. Retrieved May 8, 2015.
FDA Approved New Treatment for Hepatitis C Cure. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376449.htm, U.S. Food and Drug Administration. Retrieved May 8, 2015.
Helpful Tips When Facing Chronic Hepatitis C. http://www.olysio.com/sites/default/files/pdf/fact-sheets.pdf, Janssen Therapeutics. Retrieved May 8, 2015.
Highlights of Prescribing Information - OLYSIO. http://www.olysio.com/shared/product/olysio/prescribing-information.pdf, Janssen Therapeutics. Retrieved May 8, 2015.